Celularity (CELU)
NASDAQ:CELU
Want to see CELU full AI Analyst Report?
Top Page
Celularity
(NASDAQ:CELU)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.70
▼(-44.24% Downside)
Action:Reiterated
Date:06/13/26
The score is held down primarily by weak financial performance (ongoing losses, revenue contraction, and negative equity) and bearish technicals (below major moving averages with negative MACD). Corporate events add near-term risk due to Nasdaq compliance concerns, while valuation provides little support given negative earnings and no dividend.
Positive Factors
Strategic refocus and asset monetization
The NexGel divestiture monetized non-core biomaterials for $13.3M, cut nearly $13M of debt, and shifts resources to core cell-therapy programs. This strengthens near-term liquidity, lowers interest burden, and concentrates management and capital on higher-value therapeutic development and commercialization.
Negative Factors
Weakened balance sheet / negative equity
Negative shareholders' equity and elevated leverage materially reduce financial flexibility. This raises refinancing and covenant risk, increases the likelihood of dilutive financings or restrictive terms, and constrains the company's ability to fund R&D and commercial scale-up without costly external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic refocus and asset monetization
The NexGel divestiture monetized non-core biomaterials for $13.3M, cut nearly $13M of debt, and shifts resources to core cell-therapy programs. This strengthens near-term liquidity, lowers interest burden, and concentrates management and capital on higher-value therapeutic development and commercialization.
Read all positive factors
Celularity (CELU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.04M
Dividend YieldN/A
Average Volume (3M)206.82K
Price to Earnings (P/E)―
Beta (1Y)3.03
Revenue Growth-51.03%
EPS Growth-35.20%
CountryUS
Employees120
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap2.81
Enterprise Value/Revenue2.22
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda-0.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Celularity Business Overview & Revenue Model
Company Description
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious condi...
How the Company Makes Money
null...
Celularity Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.55M | 54.22M | 22.77M | 17.98M | 21.34M |
| Gross Profit | 20.19M | 39.23M | 6.75M | -1.69M | 11.68M |
| EBITDA | -77.66M | -43.71M | -183.95M | -138.83M | -88.11M |
| Net Income | -91.80M | -57.89M | -196.29M | 14.19M | -100.12M |
Balance Sheet | |||||
| Total Assets | 107.33M | 132.68M | 143.89M | 401.07M | 414.13M |
| Cash, Cash Equivalents and Short-Term Investments | 6.17M | 738.00K | 227.00K | 13.97M | 37.24M |
| Total Debt | 40.90M | 68.84M | 65.42M | 65.59M | 31.14M |
| Total Liabilities | 145.39M | 123.84M | 102.93M | 202.16M | 314.71M |
| Stockholders Equity | -38.06M | 8.84M | 40.96M | 198.90M | 99.42M |
Cash Flow | |||||
| Free Cash Flow | -13.25M | -6.56M | -42.73M | -143.11M | -116.30M |
| Operating Cash Flow | -13.25M | -6.40M | -38.69M | -137.88M | -110.10M |
| Investing Cash Flow | 0.00 | 514.00K | -4.05M | -5.24M | -5.90M |
| Financing Cash Flow | 18.65M | 6.70M | 24.09M | 119.84M | 98.56M |
Celularity Technical Analysis
Negative
1.25
Price Trends
1.01
Negative
1.14
Negative
1.51
Negative
Market Momentum
-0.06
Positive
34.53
Neutral
17.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 1.25 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 1.01, and below the 200-day MA of 1.51, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 34.53 is Neutral, neither overbought nor oversold. The STOCH value of 17.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.
Celularity Risk Analysis
Celularity disclosed 76 risk factors in its most recent earnings report. Celularity reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celularity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $46.01M | -2.88 | -0.97% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $320.52M | -9.41 | -60.73% | ― | -78.29% | 54.16% | |
42 Neutral | $21.04M | -0.20 | 411.46% | ― | -51.03% | -35.20% | |
42 Neutral | $5.02M | -0.12 | -1292.87% | ― | ― | -72.78% |
* Healthcare Sector Average
CELU
Celularity
0.71
-1.04
-59.31%
LTRN
Lantern Pharma
3.88
0.83
27.21%
STTK
Shattuck Labs
4.94
3.93
389.11%
FBLG
FibroBiologics, Inc.
0.93
-15.24
-94.24%
Celularity Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Celularity Faces Nasdaq Listing Compliance Risk After Notice
Negative
Jun 12, 2026
On June 9, 2026, Celularity Inc. disclosed that it received a notice from Nasdaq stating that the company’s market value of listed securities had fallen below the $35 million minimum required for continued listing on the Nasdaq Capital Marke...
Business Operations and StrategyExecutive/Board Changes
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Positive
Jun 3, 2026
On May 29, 2026, Celularity appointed industry veteran Rick Gonzalez as Chief Commercial Officer to lead global commercial strategy for its placental-derived regenerative medicine portfolio, including cenplacel-L and the Lifebank cellular banking ...
Business Operations and StrategyLegal ProceedingsPrivate Placements and Financing
Celularity Enters Settlement, Restructuring Financing Obligations
Neutral
May 28, 2026
On May 21, 2026, Celularity Inc. entered into a Settlement Agreement with Helena Global Investment Opportunities 1 Ltd., resolving disputes that arose after Helena exchanged its Series A Convertible Preferred Stock for a convertible promissory not...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy
Neutral
Apr 21, 2026
On April 17, 2026, Celularity amended its asset purchase and exclusive license agreement with NexGel, confirming total consideration of $13.3 million, including $8.3 million in cash at commencement and a $5.0 million convertible note, and revising...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.